Skip to content

Adrenocortical cancer specialist centres NSW

Criteria for a specialist adrenocortical cancer centre

  1. Access to an onsite specialist multidisciplinary cancer care team (MDT) [1, 2]
  2. Recommended core membership of an endocrinologist with a special interest in adrenal cancer, a minimum of two surgeons, a radiologist and pathologist.[3]
  3. Additional expertise or specialist services representatives are available in MDT discussions through active participation of a medical oncologist, radiation oncologist, interventional radiologist, nuclear medicine physician, palliative care specialist and research biobanking.[4]
  4. The facility conducted surgical treatment for malignant, non-malignant and benign adrenal neoplasms that include pheochromocytoma.
  5. A major tertiary hospital with:
    • expertise to perform minimally invasive adrenal surgery and open adrenalectomy to ensure the most appropriate treatment is delivered [5];
    • access to novel therapies, clinical trials or clinical research in adrenocortical carcinoma;
    • availability of cardiothoracic and hepatobiliary subspecialties for surgical management of regional or metastatic spread of adrenocortical carcinoma;
    • availability of genetic services or genetic counselling.

Availability of a multidisciplinary cancer care team

People diagnosed with adrenocortical cancer may have one or more types of treatments, including laser therapy, surgery, chemotherapy and radiotherapy.

The involvement of a multidisciplinary cancer care team is required [1]. This team brings together health care professionals from different specialties to discuss a patient’s cancer diagnosis and staging, and their treatment options. It also enhances communication and care co-ordination between the specialists involved in a patient’s care.

International studies show that patients overseen by a multidisciplinary cancer care team experience better outcome after cancer treatment [2].

Actions for Health Professionals

Actions for Health Professionals

Patient referral

Patients with a suspected or confirmed bladder cancer should be referred to a specialist who is a member of a multidisciplinary cancer care team, and practices at one of the specialist centres listed below.

Even if surgery does not seem likely at the time of referral, involvement of an appropriate a multidisciplinary team (MDT) early in the cancer journey is recommended to ensure optimal assessment, care, and outcomes.

The Canrefer website allows you to find cancer specialists who are MDT members, and has information about cancer services, optimal care pathways, and patient resources.

Smoking cessation support

Evidence suggests that tobacco cessation following cancer diagnosis improves survival. It also reduces treatment-related complications (6, 7). Health professionals should discuss tobacco use with all patients and provide appropriate cessation support.

List of public specialist centres for adrenocortical cancer surgery

Local health district

Hospital

Multidisciplinary care team

Northern Sydney

Royal North Shore 

Royal North Shore Hospital Endocrine Cancer MDT

Western Sydney

Liverpool 

Liverpool-Macarthur Adrenal and Thyroid Cancer MDT

 

List of private specialist centres for adrenocortical cancer surgery

Local health district

Hospital

Multidisciplinary care team

South Eastern Sydney

St George Private Hospital

Liverpool-Macarthur Adrenal and Thyroid Cancer MDT

References 

 

  1. Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, De Krijger RR, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. European journal of endocrinology. 2018;179(4):G1-G46.
  2. Glover AR, Ip JC, Zhao JT, Soon PS, Robinson BG, Sidhu SB. Current management options for recurrent adrenocortical carcinoma. OncoTargets and therapy. 2013;6:635.
  3. Wängberg B, Khorram-Manesh A, Jansson S, Nilsson B, Nilsson O, Jakobsson C, et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocrine-related cancer. 2010;17(1):265.
  4. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P, Group AIRS. The Italian registry for adrenal cortical carcinoma: analysis of a multiinstitutional series of 129 patients. Surgery. 1996;119(2):161-70.
  5. Gratian L, Pura J, Dinan M, Reed S, Scheri R, Roman S, et al. Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States. Annals of surgical oncology. 2014;21(11):3509-14.
  6. Hounsome L, Verne J, Persad R, Bahl A, Gillatt D, Oxley J, et al. An audit of urological MDT decision making in the South West of England. Journal of Clinical Urology. 2018;11(4):254-7.
  7. Warren GW, Sobus S, Gritz ER. The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. The Lancet Oncology. 2014;15(12):e568-e80.